| GRP94 Protein | |
|---|---|
| Protein Name | GRP94 Protein |
| Gene Symbol | HSP90B1 |
| UniProt ID | P14625 |
| PDB Structures | 5E84, 5E85, 2OHR |
| Molecular Weight | 90 kDa |
| Subcellular Localization | Endoplasmic Reticulum Lumen |
| Protein Family | Hsp90 Family |
GRP94 is a protein involved in protein folding and ER homeostasis.[1] This protein plays important roles in the endoplasmic reticulum where it assists in protein folding and quality control.[2] In the context of neurodegenerative diseases, GRP94 is implicated in Alzheimer's disease, Parkinson's disease, and other disorders through various mechanisms.[3]
GRP94 (also known as gp96) has an N-terminal ATP-binding domain, a middle domain involved in client protein binding, and a C-terminal dimerization domain. Like other Hsp90 family members, it forms homodimers. The protein has an ER retention signal (KDEL sequence) at its C-terminus. GRP94 has a unique hydrophobic pocket for client protein binding that differs from cytosolic Hsp90. The protein undergoes conformational changes during its ATPase cycle.
GRP94 is a major endoplasmic reticulum chaperone protein that plays essential roles in protein folding, assembly of protein complexes, and quality control. Unlike cytosolic Hsp90, GRP94 has distinct client proteins including immunoglobulins, integrins, Toll-like receptors, and insulin-like growth factors. It participates in the unfolded protein response (UPR) and ER-associated degradation (ERAD). GRP94 also has roles in antigen presentation and immune responses.
GRP94 is implicated in neurodegenerative diseases through its role in ER stress response. In Alzheimer's disease, GRP94 expression is altered and it may interact with amyloid precursor protein and presenilins. It helps manage protein folding stress in neurons. In Parkinson's disease, GRP94 may assist in clearing alpha-synuclein aggregates through ERAD. In ALS, GRP94 aggregates are found in motor neurons. Targeting GRP94 with inhibitors is being explored for cancer therapy, with implications for understanding neurodegeneration.
GRP94 is being explored as a therapeutic target primarily in cancer, where its inhibition can disrupt tumor cell protein homeostasis. Specific GRP94 inhibitors include Geldanamycin derivatives (17-AAG, 17-DMAG). In neurodegeneration, enhancing GRP94 function through pharmacological chaperones may be beneficial. The protein's role in antigen presentation also makes it relevant for immunotherapy approaches.